首页> 中文期刊> 《生物医学研究杂志(英文版)》 >A meta-analysis of caspase-8-652 6N del polymorphism and digestive tract cancer risk

A meta-analysis of caspase-8-652 6N del polymorphism and digestive tract cancer risk

             

摘要

Caspase-8 (CASP8) is one key regulator of apoptosis ofT lymphocytes and is encoded by the CASP8 gene.It has been reported that the six-nucleotide deletion polymorphism (-652 6N del) of the CASP8 gene had effect on some cancer risk.Few studies explored the association between CASP8 gene polymorphism and digestive tract cancer risk.To evaluate the association between the CASP8-652 6N del polymorphism and the risk of digestive tract cancer,we conducted this meta-analysis.We found that CASP8-652 6N del polymorphism was associated with a significantly reduced risk of digestive tract cancer in the co-dominant model (del/del vs.ins/ins:OR =0.82,95%CI =0.72-0.95;del/ins vs.ins/ins:OR =0.92,95%CI =0.87-0.97;dominant model (del/ins + del/del vs.ins/ins:OR =0.91,95%CI =0.87-0.96,recessive model:del/del vs.del/ins + ins/ins:OR =0.85,95%CI =0.75-0.97).In the stratified analysis by cancer types,we found that all genetic models had protective effect on gastric cancer.Similar results were observed for colorectal cancer under heterozygote comparison and dominant model,but not under homozygote comparison or recessive model.In addition,a significantly decreased risk was found on esophageal cancer for most genetic models,except heterozygote comparison.When stratified by ethnicity and source of control,an evidently decreased risk was identified in the Asian populations and population-based studies.In conclusion,there exists an association between the CASP8-652 6N del polymorphism and reduced digestive cancer risk,especially among Asians and population-based studies.

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2019年第3期|173-180|共8页
  • 作者单位

    Department of Oncology, the Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing, Jiangsu 210000, China;

    Departments of Pathology, the First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu 210009, China;

    Department of Oncology, the Third Affiliated Hospital of Nanjing University of T.C.M, Nanjing, Jiangsu 210000, China;

    Oncology, the First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu 210009, China;

    Pneumology, the First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu 210009, China;

    Oncology, the First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu 210009, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 R735.1-3;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号